← Back to Search

Virus Therapy

ERAS-801 for Glioblastoma

Phase 1
Waitlist Available
Research Sponsored by Erasca, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021 criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed up to 24 months from time of first dose
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of a new drug, ERAS-801, for people with a certain type of brain tumor.

Who is the study for?
This trial is for adults over 18 with recurrent glioblastoma who can take pills orally and have good organ function. They must be able to consent to the study and follow its procedures. People with allergies to ERAS-801, past EGFR inhibitor treatments for glioblastoma, significant heart disease, active infections needing treatment, or gastrointestinal issues affecting drug absorption cannot join.Check my eligibility
What is being tested?
The trial tests different doses of a new medication called ERAS-801 in patients with recurrent glioblastoma to find the safest and most effective dose level. It also looks at how well it works against tumors and studies how the body processes the drug.See study design
What are the potential side effects?
Potential side effects of ERAS-801 are not specified but may include typical reactions related to oral medications targeting brain tumors such as headaches, nausea, fatigue, or other symptoms depending on individual tolerance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My condition is Glioblastoma, IDH wild type.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed up to 24 months from time of first dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed up to 24 months from time of first dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Dose Limiting Toxicities (DLT)
Maximum Tolerated Dose (MTD)
+1 more
Secondary outcome measures
Area under the curve
Duration of Response (DOR)
Half-life
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose Expansion (Part 2)Experimental Treatment1 Intervention
ERAS-801 will be orally administered at the recommended dose (as determined from Part 1) to study participants with recurrent GBM harboring alterations in EGFR.
Group II: Dose Escalation (Part 1)Experimental Treatment1 Intervention
ERAS-801 will be orally administered to study participants with recurrent GBM in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.

Find a Location

Who is running the clinical trial?

Erasca, Inc.Lead Sponsor
7 Previous Clinical Trials
1,111 Total Patients Enrolled
Les BrailStudy DirectorMedical Director
Sachin Pai, M.D.Study DirectorMedical Director

Media Library

ERAS-801 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05222802 — Phase 1
Glioblastoma Research Study Groups: Dose Escalation (Part 1), Dose Expansion (Part 2)
Glioblastoma Clinical Trial 2023: ERAS-801 Highlights & Side Effects. Trial Name: NCT05222802 — Phase 1
ERAS-801 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05222802 — Phase 1
~10 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top